Isto Technologies, Inc.
HCID Member | Medical Devices & Tech
1155 Olivette Executive Parkway, Suite 200
St. Louis, MO 63132 USA
phone: (314) 995-6049
fax: (314) 995-6025
Symbol Private
Founded 0
Employees 35
www.istotech.com
Research Sector Medical Devices & Tech
Summary Description
Cell-Based Technologies and Biomaterials for Orthopedics Treatment
Management
Mitch Seyedin, Ph.D., President, Scott Gill, Chief Financial Officer, Blake Miles, VP Sales, Penny White, VP Regulatory Affairs and Quality Assurance, Gary Gage, VP Program Management
Keywords
orthopedics, cartilage and bone regeneration, regenerative technologies, spine and knee therapy, injectable cell therapy, disc nucleus repair, live cartilage implant, bone graft extender, spine fusion, bone growth, biologics, biomaterials, osteoarthritis

Comment | Printable Version | Aug. 26, 2008
If you work for Isto Technologies, Inc. and want to update this profile, click here

Description
ISTO Technologies is an orthobiologics company focused on the development and commercialization of its proprietary and patent-protected cell-based technologies designed to regenerate and restore damaged cartilage and bone. Current applications include spinal therapy, sports medicine and trauma.
Products / Services
InQu, a synthetic bone graft substitute, has FDA approval for use as an extender in the spine. InQu results show equivalence to autograft alone in producing solid fusion in the posterolateral spine. DeNovo ET is a scaffold-free living cartilage implant in clinical trials designed for the repair and regeneration of knee cartilage, offering optimal integration of cartilage into host tissue. NuQu, currently in early stage development, is an injectable cell-based therapy aimed at resolving the cause of back pain associated with degenerative disc disease.
Technology / Differentiation
A combination of hyaluronic acid and PLGA, InQu provides surgeons with a unique microenvironment conducive to bone formation. DeNovo uses ISTO's patented cell-based technology to harness the natural healing power of juvenile cartilage cells to create a living cartilage implant, which ultimately exhibits biochemical properties similar to those of articular cartilage found in young, healthy joints. It has been proven to generate cartilage 100 times more effectively than competing technologies utilizing adult cartilage cells. In addition, ISTO's cell expansion technology allows for commercial scalability and broad clinical applications.
Market / Customers
ISTO's target markets are patients suffering from pain related to damage to the knee and/or spinal tissue, as well as surgeons specializing in the areas of spine, sports medicine, and other select orthopedic markets. Back and knee pain, mostly due to the degeneration of the spinal disc and knee cartilage, are the leading causes of disability and pain in people over the age of 18 in the United States. Over one million patients undergo surgery each year in an attempt to alleviate the pain associated with cartilage degeneration.
Funding
Major investors include Alafi Capital Company, LLC, Ascension Health Ventures, LLC, Life Science Partners, Mid-American Transplant Services, and Zimmer,
Status
ISTO received 510(k) approval for InQu in 2007 and have launched commercial sales in 2008. ISTO and Zimmer, Inc. are continuing with development and clinical trials for DeNovo ET under the terms of their collaboration agreement executed in 2002. ISTO's announced its plans to initiate Phase I/II clinical trials for NuQu in 2008.


2008-11-23-2852